Oct 2020 $13 M No. 5 $10 to $50 million 12
Primmune Therapeutics, Inc.: Raise no. 5, Oct 2020 × Investors in this round 12 investors had bought by the notice of Nov 6, 2020: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $24 M offered; $11 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles McDermott · Executive Officer, Director James R. Appleman · Executive Officer, Director Paulo S. Rangel · Executive Officer Amir S. Nashat · Director Andrew S. Rubinstein · Director Scott S. Morenstein · Director Todd J. Harris · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paulo S. Rangel, Chief Business Officer. Source: SEC Form D, newest notice filed Nov 6, 2020. Read the notice at the SEC .
equity SEC Feb 2020 $3 M No. 4 $2 to $10 million 2
Primmune Therapeutics, Inc.: Raise no. 4, Feb 2020 × Investors in this round 2 investors had bought by the notice of Mar 17, 2020: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles McDermott · Executive Officer, Director James R. Appleman · Executive Officer, Director Paulo S. Rangel · Executive Officer, Director Scott S. Morenstein · Director Todd J. Harris · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paulo S. Rangel, Chief Business Officer. Source: SEC Form D, newest notice filed Mar 17, 2020. Read the notice at the SEC .
options SEC Feb 2019 $2 M No. 3 $2 to $10 million 17
Primmune Therapeutics, Inc.: Raise no. 3, Feb 2019 × Investors in this round 17 investors had bought by the notice of Mar 17, 2020: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $4 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles McDermott · Executive Officer, Director James R. Appleman · Executive Officer, Director Paulo S. Rangel · Executive Officer, Director Scott S. Morenstein · Director Todd J. Harris · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paulo S. Rangel, Chief Business Officer. Source: SEC Form D, newest notice filed Mar 17, 2020. Read the notice at the SEC .
options SEC Jul 2018 $1 M No. 2 Under $2 million 19
Primmune Therapeutics, Inc.: Raise no. 2, Jul 2018 × Investors in this round 19 investors had bought by the notice of Mar 17, 2020: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $4 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles McDermott · Executive Officer, Director James R. Appleman · Executive Officer, Director Paulo S. Rangel · Executive Officer, Director Scott S. Morenstein · Director Todd J. Harris · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paulo S. Rangel, Chief Business Officer. Source: SEC Form D, newest notice filed Mar 17, 2020. Read the notice at the SEC .
options SEC Oct 2017 $2 M No. 1 Under $2 million 36
Primmune Therapeutics, Inc.: Raise no. 1, Oct 2017 × Investors in this round 36 investors had bought by the notice of Jan 30, 2018: 36 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $360,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James R Appleman · Executive Officer, Director Paulo S Rangel · Executive Officer, Director Todd J Harris · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “A portion of the proceeds will be used to pay salaries of executive officers.”Signed by Paulo S. Rangel, President. Source: SEC Form D, newest notice filed Jan 30, 2018. Read the notice at the SEC .
options SEC